OrBec® Clinical Update - September 15, 2011 - 9 AM Eastern TimeVision, Integrity, Expertise
Soligenix, Inc. is a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. Soligenix's lead product, orBec® (oral beclomethasone dipropionate or BDP), is a potent, locally acting corticosteroid being developed for the treatment of acute gastrointestinal Graft-versus-Host disease (GI GVHD), a common and potentially life-threatening complication of allogeneic hematopoietic cell transplantation.
orBec®
orBec® represents a first-of-its-kind oral, locally acting therapy tailored to treat the GI manifestation of GVHD by reducing the need for systemic immunosuppressive drugs to treat GI GVHD. Click here to learn more about orBec®.
Latest News
Tuesday, January 31, 2012
Soligenix Announces 1 for 20 Reverse-Split of its Common StockThursday, January 26, 2012
Soligenix Receives $574,000 in Non-Dilutive Financing from New Jersey’s Technology Business Tax Certificate Transfer ProgramWednesday, January 18, 2012
Soligenix Demonstrates Robust Stability Results with its SGX204 Anthrax VaccinePartnering with Us
Soligenix is interested in identifying new partnership and merger opportunities for its existing products as well as new in-licensing candidates in the areas of HSC transplant, supportive cancer care, gastrointestinal and biodefense.